Search Results 331-340 of 14945 for alt

  1. MSC for Occlusive Disease of the Kidney - Clinical Trials

    ... ALT or AST more than 2 x normal, Prothrombin time (INR>1.4), Hemoglobin <10.0 g/dL; Clinically significant medical conditions within the six months before ...

  2. Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer - Mayo Clinic

    ... ALT value must be =< 3 x ULN; if both were performed, the AST must also be =< 3 x ULN; if AST and/or ALT is >= ULN but =< 3 x ULN, serologic testing for ...

  3. ALSENLITE: Senolytics for Alzheimer's Disease - Mayo Clinic

    AST/ALT > 2.5x upper limit normal 14. Presence of significant liver disease with total bilirubin > 2X upper limit or as per clinical judgment 15. Inability ...

  4. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    Adequate biochemistry laboratory results (AST/SGOT and ALT/SGPT ≤ 3.0 x upper limit of normal; bilirubin ≤ 2.0 mg/dL; creatinine clearance of ≥ 40 mL/min).

  5. Dr. Ahlquist Archives - Mayo Clinic News Network

    ... alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Cambria","serif ...

  6. A Study of 9-ING-41 in Patients with Advanced Cancers - Mayo Clinic

    aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 5 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with ...

  7. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

    ... (ALT) ≤ 3.0 × ULN, and albumin ≥ 3.0 g/dL;; Hepatic function for subjects with liver metastases: bilirubin ≤ 1.5 × ULN, AST, ALT, and GGT ≤ 5.0 × ULN ...

  8. Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy - Mayo Clinic

    AST or ALT < 2.5 times ULN for age; Not pregnant or nursing; Negative pregnancy test (if patient has child-bearing capacity); Fertile patients must use ...

  9. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    Participation eligibility · AST or ALT > 2.5 x ULN; · Total bilirubin ≥ 1.5 x ULN; · INR > 1.5 x ULN in the absence of therapeutic anticoagulation; · PTT or aPTT > ...

  10. Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma - Mayo Clinic

    Hepatic: bilirubin <1.5 X Upper Limit of Normal (ULN); alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ...